Document is current
Any future updates will be listed below
-
Authors
de Bray, Anne
Roberts, Anna G.
Armour, Sarah
Tong, Jason https://orcid.org/0000-0003-1027-3662
Huhn, Christiane https://orcid.org/0000-0001-9862-8784
Gatin-Fraudet, Blaise
Roßmann, Kilian
Shilleh, Ali H.
Jiang, Wanqing
Figueredo Burgos, Natalie S.
Trott, James P. P.
Viloria, Katrina
Nasteska, Daniela
Pearce, Abigail https://orcid.org/0000-0001-9845-0541
Miyazaki, Satsuki https://orcid.org/0000-0003-1781-1590
Tomlinson, Jeremy W. https://orcid.org/0000-0002-3170-8533
Owen, Dylan M. https://orcid.org/0000-0002-5284-2782
Nieves, Daniel J. https://orcid.org/0000-0002-0873-4418
Ast, Julia https://orcid.org/0000-0002-0039-4762
Cyranka, Malgorzata
Epanchintsev, Alexey
Ämmälä, Carina
Reimann, Frank https://orcid.org/0000-0001-9399-6377
Soykan, Tolga
Ladds, Graham https://orcid.org/0000-0001-7320-9612
Adriaenssens, Alice E. https://orcid.org/0000-0002-1279-4763
Trapp, Stefan https://orcid.org/0000-0003-0665-4948
Jones, Ben https://orcid.org/0000-0003-0461-2584
Broichhagen, Johannes https://orcid.org/0000-0003-3084-6595
Hodson, David J. https://orcid.org/0000-0002-8641-8568
- License Information
-
More Information
Article History
Received: 31 July 2024
Accepted: 24 June 2025
First Online: 19 August 2025
Competing interests
: J.A., M.C., A.E. and C.A. are employees of Novo Nordisk A/S. A.E.A. is an employee of AstraZeneca plc. University of Birmingham and Leibniz-Forschungsinstitut für Molekulare Pharmakologie have filed a patent (WO2024133236, ‘Peptide conjugates for labelling endogenous GIPR and GLP1R’, inventors David J. Hodson and Johannes Broichhagen), which covers daLUXendins described in the present study. Oxford University Innovation filed a PCT patent application on 14 March 2025 (PCT/GB2025/050523, entitled ‘Combination therapy’ and with the inventors being David J. Hodson, Katrina Viloria, Ali Shilleh and Martin Hewison) that encompasses elements of the work described in the present study. This PCT patent application is due to be published on 14 September 2025. D.J.H. and J.B. receive licensing revenue from Celtarys Research for the provision of GLP1R/GIPR chemical probes used in the present study, including LUXendins, sGIPs and daLUXendins. The remaining authors declare no competing interests.
